Ebola Vaccine Market to receive overwhelming hike in Revenues by 2026

Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus disease, symptomatic treatment such as maintaining electrolyte balance, imagining required oxygen level, and treating infectious condition might help in improving patient’s health. Most of vaccines to prevent Ebola virus disease are under different developmental stage.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1365

Increasing number of Ebola cases in affected regions and new vaccine development for this are expected to be factors driving growth of the market

Increasing mortality rates due to Ebola is expected to be a major factor for growth of the market. According to World Health Organization, in January 2018, around 50% people infected with EVD, have died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal, and Mali, Nigeria were affected with EVD. In 2014–16, outbreak in West African countries such as Siberia, Leone, and Guinea, lead to deaths of around 11,300 individuals. Some cases were observed during 2014–16 outbreak in the U.S., Spain, Italy, the U.K. among people that travelled to affected African countries and people who came in contact with infected patients. In May 2017, WHO declared outbreak of EVD in Democratic Republic of Congo. There is still fear about potential outbreak of EVC in vulnerable regions of Western Africa which earlier faced EVD outbreak due to gaps in public health infrastructure.Various institutes and pharmaceutical companies are focusing on developing vaccines against EVD.

According to study published in the journal, The Lancet, in December 2016, rVSV-ZEBOV also known as V920 vaccine, which is jointly developed by Newlink Genetics and Merck and Company, was found to be effective in protection against EVD in phase three trial. rVSV-ZEBOV uses strain of Zaire Ebola virus. Merck is planning to file for final marketing approval of its EVD vaccine with the U.S. FDA in 2018. Moreover, it produced 3,00,000 vaccines, in case of fresh outbreak in vulnerable regions. Various key players are focusing on developing vaccines for EVD, in order to expand its market share. For instance, GlaxoSmithKline developed CAd3-ZEBOV vaccine, derived from chimpanzee adenovirus and was tested by National Institute of Allergic and Infectious Disease, which started its phase three trials in February 2016. Janssen Pharmaceutical’s Ad26-ZEBOV is an experimental vaccine under development and currently in phase one. In 2014, Novavax Inc. developed Ebola vaccine by using its proprietary recombinant technology.

Ebola Vaccine Market Taxonomy:

On the basis of virus strain, the global Ebola vaccine market is segmented into:

  • Recombinant vesicular stomatitis virus-Zaire Ebola virus
  • Chimpanzee Adeno virus type 3-Zaire Ebola virus
  • Adeno virus serotype 26- Zaire Ebola Virus

In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells.

GAVI is an international organization (global Vaccine Alliance) paid US$ 5 million to Merck & Company in 2016 for procurement of the vaccine (V 920 vaccine). Key players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, and Novavax Inc.

Insulin Delivery Devices Market Report Study, Synthesis and Summation 2018-2026

Direct subcutaneous insulin injection are the most common form of drug delivery, using a needle and syringe. There are different types of insulin delivery devices available including, syringes, pens, jet injectors, and insulin pumps. Insulin can be packaged in vials (bottles), cartridges or prefilled pens. However, several disposable and reusable pen devices have been developed that provide options for delivering rapid insulins and insulin premixes. Type or dosage of insulin can be changed according to the requirements to meet the individual needs of the patient Manufacturers are focusing on designing products, which are cost effective for people with diabetes which is expected to propel the growth of the insulin delivery devices market. For instance, in July 2017, Becton, Dickinson and Company launched BD Viva pen needles, have a highly engineered needle tip design for improved comfort and considered as the most cost-effective option for insulin-injecting people with diabetes in the UK.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1352

Market Dynamics

The market is gaining significant traction due to increasing prevalence of diabetes, and new innovations in terms of design. According to the World Health Organization, in 2016, an estimated 422 million adults are living with diabetes globally. The major spike in incidence of type 2 diabetes over the last decade is mainly attributed to rising prevalence of obesity. However, high cost of some insulin delivery devices is expected to be a restraining factor for the market growth. For instance, insulin analogs supplied in cartridges or prefilled pens have a higher per unit of insulin cost than insulin analogs supplied in vials. For example, one vial (1000 U) of insulin costs US$ 105.95, which equates to a cost of 10.6 cents per unit of insulin. Five prefilled insulin pens containing insulin glulisine (total of 1500 U) have a total cost of US$ 201.01, equating to a cost of 13.4 cents per unit of insulin (26% over the cost of insulin glulisine supplied in a vial).

Key features of the study:

  • This report provides in-depth analysis of the insulin delivery devices market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: (2017–2025), considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global insulin delivery devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans

Increasing adoption of advanced devices for insulin delivery is driving growth of the market

Increasing awareness among population regarding insulin delivery devices coupled with high demand for insulin administration for diabetes control are the factors driving growth of the market. Among region, North America, accounted for largest market share in insulin delivery devices, followed by Europe, owing to high prevalence of lifestyle associated diseases, implementation of awareness programs regarding diabetes, and high adoption of advanced medical devices. For instance, in 2010, according to Journal of Diabetes Science and Technology, majorly insulin pumps were used on the American side of the Atlantic than on the European side, which is projected to propel demand for insulin pumps over the forecast period.

Key players in the market are focusing on developing next generation devices to remain competitive, while seeking ways to enhance their design capabilities. For instance, in October 2017, Eli Lilly and Company announced its plans to invest US$ 72 million in an insulin manufacturing project at one of its Indianapolis facilities. The investment will be used to replace an existing insulin vial filling line and allow Lilly to meet growing demand for its insulins – including Humalog (insulin lispro) and Humulin (human insulin) – while upgrading to state-of-the-art technology and preparing for its insulin pipeline.

Rising Adoption of Healthcare in North America will Boost The Lab Automation Market Growth

Lab automation systems incorporates use of high end equipment’s and software into various laboratory procedure such as sample preparation with reagent mixing, pipetting out sample, performing sample analysis for characterization of the compound in the sample, sensitive lab ware movement, liquid dispensing assay performance, and cell culture preparation. Lab automation systems provides advantage such as precision in operations, saving time by performing batch operations, and accuracy of data due to minimizing human error. It also prevents sample wastage (in case sample having very low yield). Increasing applications of lab automation in research laboratory is creating potential opportunity for growth of the market.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1334

Market Dynamics

Major factor driving growth of the lab automation market include the need for accurate diagnosis in less time with minimum error. For instance, ELISA test is utilized in diagnosis of diseases such as Zika, AIDS, rotavirus, syphilis, and chickenpox. These diseases has high prevalence worldwide and frequent outbreaks of the same as infectious disease may promote use of automated ELISA systems. Increasing use of the DNA sample in diagnostics with tedious procedure involved in it is expected to propel growth of the lab automation market. Pharmaceutical companies worldwide are involved in genomics research, there is increasing research spending and collaboration with genomics firms by pharmaceutical and biotechnological companies in which lab automation will play crucial role. In April 2016, AstraZeneca launched project to sequence genome of over 2 million people by collaborating with biotech firm Human Longetivity, Inc., and other academic institutions. In March 2015, Genomics England announced to partner with 10 pharmaceutical and biotechnological companies to develop new diagnostics and treatments for cancer patient and rare disease, using the genomic sequences gathered through the 100,000 Genomes Project.

However, high cost associated with lab automation equipment is hindering growth of the market, as these equipment’s are costly to acquire by small research institutions reducing the wide adoption of the system.

Key features of the study:

  • This report provides in-depth analysis of lab automation market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global lab automation market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Pharmaceutical and biotech companies are focused on development of novel molecules for treatment of chronic disease such as cancer and cardiovascular disease, which require utilization of lab automation equipment, which in turn is expected to drive growth of the lab automation market. According to report published by International Federation of Pharmaceutical Manufacturer and Association in 2017, pharmaceutical industry invests US$ 149.8 billion on research and development annually. Furthermore, more than 7000 compounds are in preclinical stage of development out of which 56 were launched in 2015 and in 2011 – 2015 around 225 new chemical and biological entities were launched.

Increasing research and development in personalized medicine to drive growth of the lab automation market

Lab automation market is expected to gain significant traction in near future due to advancements in personalized medicine by utilizing tools of genome engineering. For instance, immuno-oncology utilizes CAR-T cell therapy for isolation of T cells from patients, which then genetically engineered to produce receptors on their surface called chimeric antigen receptors and such cells are multiplied by in vitro methods. Most of the steps involved in this procedure require lab automation equipment. For instance, automated liquid handling system would boost the assay and sample preparation of CAR-T cells, automated storage and retrieval system helps in efficient preservation and storage of original and multiplied T cells, which are to be administered in patient’s body.

Key players operating in the lab automation market include Tecan Group Ltd., PerkinElmer Inc., Danaher Corporation, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Hamilton Robotics, Abbot Diagnostics, Eppendorf, Roche Diagnostics, and Siemens Healthineers.

Disposable IV Therapy Products Market Set for Rapid Growth And Trend by 2026

Intravenous (IV) therapy products are used to treat a variety of conditions including dehydration and nutrient-absorption disorders. It is increasingly given at homecare and clinics to help patients feel better without clogging emergency departments. IV therapy is also commonly used as an essential part of treatment regimens by doctors and paramedics responding on air and land ambulances, chiefly in traumatic injury management.

Market Dynamics

The major factors driving growth of the disposable IV therapy products market is increasing patient volume including geriatric population base and rising incidence of chronic diseases. For instance, according to National Health Service, in 2016, patients aged 65 to 69 made up the largest age group of hospital admissions in UK. Demand for disposable IV therapy products will also experience upward momentum as clinics, hospitals, and other health care institutions adopt stringent infection prevention norms to meet standards set by the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO) and the Centers for Disease Control and Prevention (CDC). Advances in disposable IV therapy products technology is expected to have a positive impact on demand for disposable IV therapy products. Increasing introduction of novel and advanced products based on improved designs and materials is expected to drive growth of the market.

Download The PDF Brochure:  https://www.coherentmarketinsights.com/insight/request-pdf/1327

For instance, the disposable needleless connector marketed by SPECATH in 2013 is utilized as channels or injestion sites for need of IV infusion. Its particular design provides many advantages with consumers, such as convenient sterilization and no need of sealing catheter. Increasing application of infusion devices for relieving pain, growing attention towards healthcare infrastructure, and rising prevalence of chronic diseases is likely to propel the market growth.

Key features of the study:

  • This report provides in-depth analysis of disposable IV therapy products market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global disposable IV therapy products market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Detailed Segmentation:

  • Global Disposable IV Therapy Products Market, By Product Type:
    • Intravenous Sets
    • Infusion Pumps
    • Needleless Connectors
    • Other Products
  • Global Disposable IV Therapy Products Market, By End User:
    • Hospitals
    • Clinics
    • Home Healthcare
  • Global Disposable IV Therapy Products Market, By Geography:

Technological advancements in IV therapy products to accelerate the market growth

Growing focus on cost containment and cost effectiveness at health care facilities coupled with technological advances in IV therapy products have allowed the effective and safe use of IV therapies. Increasing inclination of patients towards safety-enhancing pumping instruments and needleless technologies are expected to drive growth of the disposable IV therapy products market over the forecast period. For instance, in 2014 CareFusion (a Becton Dickinson subsidiary) launched MaxZero needleless connector (zero reflux connector) that offers the same technology as the MaxPlus connector, designed to reduce the risk of occlusions and infections.

The major players operating the global disposable IV therapy products market include B. Braun Melsungen AG, Baxter, Beckton Dickinson & Company, Caesarea Medical Electronics, ICU Medical, Inc., JMS Co. Ltd., Lily Medical Corporation, Smiths Medical, and Terumo Corporation.

Surgical Staplers Market predicts rise in demand by 2026

Surgical stapler is used to close wounds, including skin incisions and bowel resections in surgical settings. It can be either reusable (made of stainless steel) or disposable (made of plastic). Disposable staplers are tailored with disposable cartridges and used on single patient, while reusable staplers can be reloaded with disposable cartridges. The stapler can be used again after sterilization. The use of surgical staplers offers efficient wound closure, faster recovery, higher accuracy, and reduced hospital stay.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1318

Market Dynamics

The major factors driving growth of the surgical staplers market include rising geriatric population and increasing prevalence of obesity requiring surgical procedures. Bariatric surgery is a group of surgical weight loss procedures aimed to help obese people. As the prevalence of obesity is growing, there is also a proportionate surge in the number of people undergoing weight loss surgeries. For instance, according to the American Society for Metabolic and Bariatric surgery report 2016, the total number of bariatric surgery completed in the U.S. in year 2011 was 158,000. Technological advancements have led to development of various unique surgical instruments and devices. For instance, the MicroCutter 5/80 launched by Dextera Surgical Inc. in 2016, is the world’s first and only 5mm surgical stapler that articulates to 80 degrees in each direction. Introduction of new products and continuing technical developments in existing products are changing the way conventional surgeries are performed. However, strict regulatory landscape, high associated cost, and wide availability of alternative techniques such as sutures can hamper the market growth.

Key features of the study:

  • This report provides in-depth analysis of surgical staplers market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global surgical staplers market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Increasing number of surgeries to augment market growth

Increasing number of surgical procedures demanding surgical staplers is expected to be a major factor driving the global surgical staplers market over the forecast period. Staples are commonly used in surgical specialties such as cardiothoracic, gynecological, gastrointestinal, head, orthopedic, hand, urologic and vascular surgery. With an increase in chronic non-communicable disorders such as thoracic and cardiac diseases, there is a simultaneous rise in associated interventions required to treat these disorders.

Increasing preference for surgical staplers over sutures to accelerate the market growth

Stapling involves minimal skin penetration in comparison to stitches and are preferred due to their ease of use, rapidity of application and are less prone to infection. Staples are less likely to cause negative skin reactions than suturing materials since they are made of stainless steel. According to a study reported in International Surgery Journal 2017, the use of stapling to close skin incision in laparotomy cases lessens surgical site infection, reduces the pain experienced by the patient and leaves lesser scars.

The major players operating in the global surgical staplers market include B. BRAUN MELSUNGEN AG, CONMED Corporation, Dextera Surgical Inc., Frankenman International Ltd., Grena Ltd., Intuitive Surgical Inc., Johnson & Johnson, Medtronic Plc, Purple Surgical and Surkon Medical.

Respiratory Devices Market: Business Planning Research, Reviews & Comparison of Alternatives

Respiratory devices or equipment are commonly used in the medical settings as per the medical condition. Ventilators are the most common tools, which are commonly used in emergency medicine and long-term critical care. In addition to the therapeutic respiratory devices, the diagnostic and monitoring devices minimize hospitalizations, thereby lowering the cost associated with medical settings.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1299

Market Dynamics

The major factor driving growth of the respiratory devices market include INCREASING prevalence of respiratory diseases such as COPD and asthma, increasing respiratory disease with rise in pollution level and rising geriatric population. According to the study by Global Burden of Disease, 2016, an estimated around 251 million cases of COPD were reported worldwide. According to the World Health Organization (WHO), 2015, an estimated 3.17 million deaths were caused by the disease accounting for 5% of all deaths. However, lack of awareness regarding the diseases harmful effects of certain respiratory care devices on neonates are the factors restraining respiratory devices market growth.

Key features of the study:

  • This report provides in-depth analysis of respiratory devices market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global respiratory devices market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Increasing admissions of critical care patients in Intensive Care Units (ICU) is expected to fuel the market growth

Increasing prevalence of chronic respiratory diseases such as asthma, chronic pulmonary lung disease, pulmonary hypertension, and occupational lung disease are the major factors augmenting growth of the respiratory devices market, owing to the pronounced need of therapeutic respiratory devices in the medical as well as in the homecare settings. According to the World Health Organization (WHO), in 2017, asthma is a major non communicable disease with an estimated 235 million people suffering from the condition.

Increasing support from international organizations for prevention of chronic respiratory diseases is expected to accelerate the market growth

Various organizations, institutions, and agencies are working towards improving the diagnosis and the medical care needed to reduce the global burden of respiratory diseases. For instance, the Global Alliance against Chronic Respiratory Diseases (GARD) was formed with the support from the World Health Organization (WHO) to control chronic respiratory diseases. GARD is a voluntary alliance of national, international organizations, and agencies from many economies. The main objective of GARD is to develop simple and affordable strategies for chronic respiratory diseases (CRD) and to encourage economies to implement health promotion and CRD prevention policies.

The major players operating the global respiratory devices market include Koninklijke Philips N.V., 3M, AstraZeneca Plc., GE Healthcare, GlaxoSmithKline Plc., Medtronic plc, Becton, Dickinson and Company, Invacare Corporation, ResMed, Inc., and CareFusion Corporation.

Swine Respiratory Disease Treatment Market Shows Expected Trend to Guide from 2018-2026 with Growth Analysis

Swine respiratory disease affects the respiratory tract of swine. It is one of the prevalent cause of death in nursery pigs and grower/finisher pigs. There are multiple pathogens, viruses, and other secondary causative agents that causes respiratory disease in swine. Primary pathogens that causes swine respiratory disease are Actinobacillus pleuropneumoniae (APP), Mycoplasma hyopneumoniae, Bordetella bronchiseptica, and Pasteurella multocida. Viral agents involved are porcine reproductive and respiratory syndrome (PRRS) virus and swine influenza virus (SIV). Various diseases that come under ambit of swine respiratory disease are mycoplasma pneumonia, swine influenza, classical swine fever atrophic rhinitis, pleuropneumonia, porcine reproductive and respiratory syndrome, and porcine circovirus type 2. These infectious agents together increase the severity of the disease.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1274

China, U.S., and E.U to drive growth of the swine respiratory disease treatment market due to high pork production

According to the factsheet by United Nations Food and Agriculture Organization (UN-FAO) worldwide there is close to one billion headcount of swine. China has highest number of headcount, followed by the U.S. and EU. These regions are expected to drive growth of the respiratory disease treatment market, owing to high pork production. As per the United States Department of Agriculture (USDA), around 108.2 million metric tons of pork was produced in 2016, which requires supply of healthy swine. Early vaccination is essential for healthy swine as respiratory disease in swine leads to lung damage, poor growth of swine, medication cost, and in turn results into lower economic efficiency for swine farmer. Therefore many of these regions opt for vaccination to prevent the respiratory disease in swine, which in turn is expected to propel growth for the swine respiratory disease treatment market. According to the study published in Virology Journal in 2017, emergence of porcine cyclovirus type 3 in pigs in regions such as China, U.S. and some part of Europe is fueling growth of the swine respiratory disease treatment market. According to Scientific Reports published in 2013, porcine reproductive and respiratory syndrome is economically most important disease of swine in North America, Europe, and Asia. North America spends around US$ 600 million annually for treatment of this disease.

However, increasing inclination of population towards adoption of vegetarian diet in China leading to lower swine farming prospect is restating growth of the swine respiratory treatment market. Also, according to the United States Department of Agriculture (USDA) cost of pork was dropping till end of 2017, which negatively affects the swine farming.

Swine Respiratory Disease Treatment Market Taxonomy:

On the basis of product type:

  • Drugs
  • Vaccines

On the basis of indication:

  • Mycoplasmal Pneumonia
  • Swine Influenza
  • Classical Swine Fever
  • Porcine Reproductive and Respiratory Syndrome (PRRS)
  • Porcine Circovirus-Associated Disease
  • Pseudorabies

On the basis of distribution channel:

  • Veterinary hospital
  • Pharmacies

Key players operating in the swine respiratory disease treatment market include Zoetis, Inc. Merck Animal Health, Bayer AG, Boehringer Ingelheim Vetmedica, Inc., Elanco Animal Health, Virbac Group, Norbrook, Ceva Santé Animale, Vetoquinol, Bimeda holdings PLC, and Agrilabs, Inc. In January 2018, FDA approved dose of 100 gram per ton feed for Lincomix (Product from Zoetis, Inc.), which contains lincomycin hydrochloride to reduce the severity of swine respiratory disease from mycoplasma hyopneumoniae. Lincomix is the only feed medication approved against mycoplasma hyopneumoniae, which is leading cause for swine pneumonia. In 2016, Gamithromycin (ZACTRAN) was approved for use in pigs by USDA. In June 2017, a team of researchers from University of Leicester isolated 20 bacteriophages that targets 72 potential drug resistant bacteria in pigs. This bacteriophages were found to be more specific for treatment of bacterial infections in pigs. MSD Animal Health (known as Merck Animal Health in the U.S. and Canada) in November 2017, signed an agreement to acquire Vilsan Pharmaceuticals which is a division of Vimar Group, based in Turkey. Vilsan Pharmaceuticals holds significant share in animal health products in Turkey.

Cell Line Development Industry Infrastructure Growth and Development 2018 to 2026

Cell line is a permanently established cell culture, which proliferates in fresh medium. Cell line development is utilized for examining efficiency of drug discovery and toxicity. It is essential for the production of recombinant proteins production such as, monoclonal antibodies, bi-specific monoclonal antibodies, growth factors, and enzymes using a wide variety of expression systems. Cell lines saves the crucial time, effort and cost by providing the high yield cells which can be used for in vitro testing and reduce chance of research drug to fail in clinical trial stage.

Download The PDF Brochure:  https://www.coherentmarketinsights.com/insight/request-pdf/1286

Development of novel therapy to drive growth of the cell line development market

Cell line development has wide application areas. Development of immunotherapy for the treatment of cancer is major application of cell line development. According to the World Health Organization factsheet 2012, cancer is one of the leading cause of death from top three causes of non-communicable disease. Pharmaceutical and biotechnological companies are focusing on developing novel therapies such as immunotherapy due to its specificity and efficiency. Cell line development helps in speeding drug discovery process and optimization of clinical trials by providing high yield of monoclonal antibodies, which is expected to fuel growth of the cell line development market.

Increasing technological advancements in cell line development are expected to boost growth of the cell line development market. For instance, in November 2017, Lonza group launched Multiplex Cell line culture using GS Xceed Gene Expression System., which helps in testing multiple drug candidMarketate at early developmental stage thereby saving four to six months, which otherwise is required in conventional development program.

North America to dominate the market for cell line development due to high investment in research by pharmaceutical companies to develop novel product

North America is expected to hold the dominant position in the global cell line development market, owing to high investment by pharmaceutical companies in developing a novel treatment product and increasing off patenting of major products, which would promote biosimilar drug development. Biosimilar drug having biological molecule needs to match in structure and composition with original product which needs cell line to confirm matching of structure and adhere to quality attribute such as glycoprofile, protein aggregation. For instance, according to 2016 report of International Trade Administration of Department of Commerce (USA), the U.S. generic drug sales reached an estimated US$ 70 billion in 2015, which represents quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favoring generics development. According to the same report, biologics account for over a third of all new drugs in clinical trials or which are waiting for FDA approval. According to Pharmaceutical Research and Manufacturers of America, companies such as Novartis AG, Merck and Company and F. Hoffmann-LA Roche AG in U.S. together invested in US$ 75 billion in research and development. Legal factors such Affordable Care Act which has already covered most of population would boost the usage for novel products as patients can get treated with insurance coverage without out of pocket expenditure on such medication .

Collaborations by cell line development companies with drug discovery companies to speed up expansion of cell line development market

Some of the major players operating in the global cell line development market include Lonza Group AG, Sigma-Aldrich Corporation, Wuxi App Tec, Inc., American Type Culture Collection, Thermo Fisher Scientific, Inc., PX’Therapeutics SA., Selexis SA, GE Healthcare, European Collection of Cell Cultures , Corning, Inc., Sartorious AG, Goodwin Biotechnology Inc., and Cleancells. These companies are entering into strategic partnership with drug discovery companies to optimize their product development:

  • In December 2017, Selexis SA and Turgut Pharmaceuticals announced to enter into a third commercial license agreement, which would provide Turgut with access to Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of biosimilar product for the treatment of two rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The companies were already in agreement (made in July 2016) to develop biosimilar products to treat inflammatory diseases and certain cancers using the SURE CHO-M Cell Lines.
  • In October 2017, Selexis SA and Pelican Therapeutics (subsidiary of Heat Biologics, Inc.) announced to enter into an agreement for the development of Pelican’s immunotherapy clinical candidates PTX-35 and PTX-15. Pelican would utilize Selexis’s SUREtechnology PlatformTM to rapidly develop high-performance research cell banks expressing two of research candidate such as PTX-35, which is humanized monoclonal antibody that is a functional agonist of human TNFRSF25, and PTX-15, which is a human TL1A-Ig fusion protein.
  • In November 2017, American Type Culture Collection announced the release of an innovative in vitro model system of cell lines for key mechanism of invasion and metastasis in lung cancer
  • In January 2018, PX’Therapeutics announced collaboration with biotech firm Advaxis for process development of immunotherapies of Advaxis

Medical Ceramics Market Set Explosive Growth to 2026

Ceramic Materials are the combination of thermal and physical qualities which are used for various medical applications for the repair and reconstruction of human body parts. This employed majorly in dental and orthopedic applications, mainly as implants or replacements. The inherent brittleness of traditional ceramics has limited their ability to compete with ductile metals and polymers for technical applications. However, over the last 100 years innovative techniques in the fabrication of ceramics have led to their use as high-tech materials. Inert bioceramic, such as ZrO2 and Al2O3, have inherently low levels of reactivity compared with other materials such as polymers and metals as well as surface reactive or resorbable ceramics and they are expected to be non-toxic, non-allergenic, and non-carcinogenic for a life-time in a human bod. This led to the early adoption of the most recent generation of instruments using an established technology in the hospitals.

Request For Sample Copy of This Research Report:  https://www.coherentmarketinsights.com/insight/request-sample/1261

Market Dynamics

The global incidence of osteoarthritis is expected to escalate which in turn increasing demand for medical ceramics implants as Osteoporosis is characterized by low bone mineral density (BMD) and deterioration of bone tissues, leading to increased risk of developing traumatic bone fractures. According to the World Health Organization (WHO), 2013, around 28.2% of the global population above 60 years of age, suffered from osteoarthritis with an estimated 80% recorded with mobility handicaps. Moreover, Growth in applications of medical ceramics for inartificial total hip, knee, shoulder, elbow, wrist bone plates, screws, wires intramedullary nails, spinal fusion alveolar bone replacements, mandibular reconstruction and tooth replacement implants has opened new growth avenues for medical ceramics market. However, although medical ceramics are known to be nontoxic, there are cases where very small traces of radioelements are found even in the ceramics that are fully refined and can have devastating effects on organs and tissues, this could hamper the growth of the market during the forecast future.

Market Taxonomy

This report segments the global medical ceramics market on the basis of material and application. On the basis of material, the market is classified into bio-inert, bio-active, bio-resorbable and piezo ceramics. Bio-inert segment is further sub-divided into Aluminum Oxide, Zirconia, Carbon and bio-active sub-divided into Hydroxyapatite (HAP), Glass and Bioglass, zirconia alumina composite. Applications of medical ceramics include surgical implants, medical tools and devices and prosthetics. Surgical implants further sub-divided into dental implants, orthopedic implants and other implants.

Key features of the study:

  • This report provides in-depth analysis of medical ceramics and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year.
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launch or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global medical ceramics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

North America market accounted for the largest market share, followed by Europe in 2016. This is owing to high usage of implantable medical devices, furthermore, rise in number of osteoporotic fractures in the U.S. and presence of relatively large number of medical device manufacturers in this region is expected to be a factor for growth of the medical ceramics market in this region. For instance, according to the National Osteoporosis Foundation (NOF), over 1.3 million osteoporotic fractures occur each year in the U.S. The market in Asia Pacific and Latin America is also expected to witness substantial growth. This is owing to rise in medical tourism for dental and orthopedic procedures. According to the study by Far International, 2016, the knee replacement surgery costs around US$ 40,000, whereas the costs in Colombia is only US$ 15,000.

Some of the key players in medical ceramics market are CoorsTek Medical, H.C. Starck GmbH, Tosoh Corporation, Noritake Co., Ltd., 3M ESPE, Morgan Advanced Materials plc, Ceramtec, Pl Ceramic GmbH, Lithoz, and Kyocera Corporation.

Anti-Venom Market Prognosticated For A Ravishing Growth By 2026

Anti-venom is a medication majorly used to treat snake bites and it can also be used to treat bites from scorpions, spiders or other reptiles. It is made by fractionating the blood of the donor (horse or sheep), which is hyper immunized with snake venom. These products are available in either lyophilized or liquid forms. Anti-venom is the only effective therapy against snake bites and they also save patients from cell and tissue necrosis, thus helping save vital organs.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1249

Market Dynamics

The incidence of animal bite such as snake, and scorpion is high. High incidence of poisonous animal bite is also expected to be a major factor driving demand for anti-venom in the near future.

For instance, according to the data published by World Health Organization (WHO), in 2018, it was estimated that globally, the incidence of snakebite is around 4.5 to 5.4 million bites from venomous and non-venomous snakes, out of which around 1.8 million to 2.7 million cases of snakebite are envenoming.

Increasing initiatives by government and various other organizations to increase awareness about snake bite and its treatment is further expected to support adoption of anti-venoms during forecast period. For instance, World Health Organization (WHO), in June 2017, added snakebite to its priority list of neglected tropical disease, which would result in more focused effort to prevent death from snakebite, thus boosting growth of the anti-venom market.

Key features of the study:

  • This report provides in-depth analysis of anti-venom market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global anti-venom market  based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans

Asia Pacific is expected to hold dominant position in the global anti-venom market owing to high incidence of snake bites

Asia Pacific anti-venom market is expected to hold the largest market share during the forecast period, owing to high incidence of snake bites in countries such as India and Bangladesh. For instance, according to the data published by Journal of the Association of Physicians of India, in 2017, around 50,000 people die in India annually, due to venomous snake bites.

High price of anti-venom and treatment procedure with anti-venoms are expected to be the major factor hindering the market growth during the forecast period. For instance, according to the data published by World Health Organization (WHO) in March 2018, in sub-Saharan Africa in 2010 and 2011, the direct cost of anti-venom alone ranged from US$ 55 to US$ 640 for an effective treatment, using recommended doses, with the average cost being US$ 124.7. Such high prices are not easily affordable by population in emerging economies.

Key players operating in the anti-venom market include BTG plc. Laboratorios Silanes, CSL Limited, Pfizer, Inc., Merck & Co., Inc., Bharat Serums and Vaccines Limited, Haffkine Bio-Pharmaceutical Corporation Ltd., Vins Bioproducts Limited, Incepta Pharmaceuticals Ltd., and Rare Disease Therapeutics Inc.